Global Amlodipine Besylate Market Research Report 2021

Amlodipine Besylate is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension and Coronary Artery Disease.

The global Amlodipine Besylate market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Amlodipine Besylate volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Amlodipine Besylate market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Amlodipine Besylate Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
2.5mg Tablets
5mg Tablets
10mg Tablets

Segment by Application
High Blood Pressure
Heart Disease

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Pfizer
Mylan
Dr. Reddy's Laboratories
Apotex
Teva Pharmaceutical
Cipla
Hikma Pharmaceuticals
Strides Pharma
Upsher-Smith Laboratories
InvaGen Pharmaceuticals
Sun Pharmaceutical
Aurobindo Pharma
Lupin Pharmaceuticals
Zydus Pharmaceuticals
Oxford Pharm
Wockhardt
Epic Pharma
CR Pharmaceutical
Alkem Laboratories
MACLEODS